Pharming Group: FDA Acceptance Of Supplemental NDA, Priority Review For Leniolisib In Children With APDS
RefinitivOkuma süresi: 1 dakikadan kısa
Pharming Group NV 
PHARM:
PHARMING GROUP ANNOUNCES U.S. FDA ACCEPTANCE AND PRIORITY REVIEW OF SUPPLEMENTAL NEW DRUG APPLICATION FOR LENIOLISIB IN CHILDREN WITH APDS AGED 4 TO 11 YEARS
PDUFA TARGET ACTION DATE SET FOR JANUARY 31, 2026
DECISION BASED ON POSITIVE PHASE III STUDY DATA
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Bu haberi okumak için giriş yapın veya sonsuza kadar ücretsiz bir hesap oluşturun